Yes, many people with diabetes can donate a kidney, but only a narrow subset qualifies, and the bar is far higher than for non-diabetic donors. The decisive factor is not the word "diabetes" itself but its type, duration, and end-organ damage. Someone with a remote history of gestational diabetes or well-controlled prediabetes may clear evaluation; someone with type 2 diabetes on insulin, or any diabetes with protein in the urine or reduced filtration, is almost always excluded. Most U.S. transplant centers treat established type 1 or type 2 diabetes as a disqualifying condition for living donation.
Why Diabetes Changes the Donation Equation
Living kidney donation removes roughly 25 to 35 percent of functional kidney mass in one operation. The remaining kidney compensates by increasing single-nephron filtration, a process called hyperfiltration, which raises pressure inside the glomerular capillaries. In a healthy donor, this adaptation is usually harmless for decades. In a donor with diabetes, the same compensation lands on kidneys already stressed by hyperglycemia.
The mechanism is worth stating precisely. Chronic high blood glucose glycates proteins in the glomerular basement membrane, thickening it and increasing its permeability. Simultaneously, diabetes dysregulates the afferent and efferent arterioles, so the pressure gradient across the filter rises. Adding surgical loss of nephron mass on top of that is a second hit on the same vulnerable structure. The result is accelerated albuminuria and faster decline in estimated glomerular filtration rate (eGFR).
In plain terms: a diabetic kidney is already working under extra pressure, and donation removes the reserve that absorbs that pressure. That is why donor selection screens for early diabetic kidney changes even when routine blood tests look normal.
The Eligibility Thresholds That Decide Most Cases
Transplant programs publish their own living-donor criteria, so thresholds vary. The following are the commonly applied cutoffs at U.S. centers, drawn from the 2017 KDIGO living kidney donor guideline and the 2020 KDIGO diabetes management guideline, which jointly inform most program protocols.
The two most consequential numbers to reconcile: an HbA1c of 6.5 percent is the diagnostic threshold for diabetes, while most donor programs set the acceptable ceiling for a diabetic candidate at roughly 7.0 percent, and many hold non-diabetic donors to below 5.7 percent. These do not contradict because one number defines disease and the other defines surgical fitness. A donor can meet the diagnostic threshold yet fail the fitness threshold.
| Criterion | Typical donor requirement | Why it excludes diabetics |
|---|---|---|
| HbA1c | Under 7.0 percent, often under 6.5 percent | Reflects chronic glycemic load on glomeruli |
| Urine albumin-to-creatinine ratio | Under 30 mg/g | Signals early diabetic nephropathy |
| eGFR | Above 80 mL/min/1.73 m², age-adjusted | Measures functional reserve left after donation |
| Diabetes duration | Under 5 to 10 years, if allowed at all | Duration predicts microvascular damage |
| Insulin requirement | Usually disqualifying | Implies beta-cell failure, higher complication risk |
| Blood pressure | Under 140/90, ideally under 130/80 | Hypertension compounds renal risk |
| Cardiovascular screening | No significant coronary disease | Diabetics carry higher perioperative cardiac risk |
The practical consequence of this table is that a person with diabetes who has an HbA1c of 6.4 percent, a urine albumin ratio of 12 mg/g, an eGFR of 95, and no insulin use may pass a permissive program. Change any single row and the calculus flips.
Quantified Risk: What the Donation Costs Over Time
Donors are not patients, and the evidence base reflects that. Most large studies exclude diabetics from the donor cohort, so the risk estimates below come from two sources: general-population diabetic kidney decline and the small published series of diabetic donors.
A non-diabetic living donor faces an estimated lifetime risk of end-stage kidney disease of roughly 0.3 to 0.5 percent, versus an age-matched non-donor risk near 0.25 percent, per a landmark 2014 JAMA study by Muzaale and colleagues. That is an absolute excess of a few tenths of a percent over a lifetime. For a diabetic donor, the excess risk is not well quantified, but the direction is clear: diabetic nephropathy progression in the general population runs at roughly 2 to 3 percent per year of eGFR loss once albuminuria is present, compared with under 1 percent per year in age-matched non-diabetics. A second hit on that trajectory is not a trivial addition.
One non-obvious detail: albuminuria often appears before eGFR falls, so a diabetic candidate with a normal eGFR can still be silently losing filtration surface. Some programs therefore require a measured, not merely estimated, GFR and a repeat albumin test to rule out transient elevation.
When Donation Is Considered and When It Is Not
The realistic answer to whether diabetics can donate a kidney depends heavily on diabetes type. The distinction matters because the underlying biology differs.
- Gestational diabetes only, resolved after pregnancy: often acceptable if glucose tolerance has normalized on repeat testing.
- Prediabetes with HbA1c 5.7 to 6.4 percent and normal albumin: sometimes acceptable at permissive centers, with closer follow-up.
- Type 2 diabetes managed by diet or metformin, short duration, no complications: occasionally accepted at selected programs, with informed consent about elevated long-term risk.
- Type 2 diabetes on insulin or with any albuminuria: essentially never accepted.
- Type 1 diabetes at any stage: disqualifying at nearly all centers because of beta-cell failure and cardiovascular risk.
The first category carries an edge case worth flagging. A woman with a remote history of gestational diabetes has a lifetime risk of progressing to type 2 diabetes of roughly 35 to 50 percent within 10 to 15 years of the affected pregnancy, per the American Diabetes Association. A program that accepts her is effectively underwriting a future diagnosis, which is why many require a normal oral glucose tolerance test at evaluation and annual screening afterward.
How the Evaluation Timeline Actually Runs
The donation process for any candidate is months long, and a diabetes diagnosis adds steps that can extend it. The timeline below reflects a typical U.S. program for a candidate with prediabetes or a borderline history; a candidate with established diabetes should expect the process to stop earlier.
| Stage | Typical duration | What happens |
|---|---|---|
| Initial screening | 1 to 2 weeks | Blood type, crossmatch, health questionnaire |
| Medical evaluation | 2 to 4 weeks | Bloodwork, HbA1c, urine albumin, eGFR, imaging |
| Specialized diabetes review | 2 to 6 weeks | Glucose tolerance testing, endocrinology input |
| Psychosocial and financial review | 1 to 2 weeks | Counseling on risks, insurance, lost wages |
| Independent donor advocate review | 1 week | Ethics and voluntariness confirmation |
| Final committee decision | 1 to 3 weeks | Multidisciplinary team approval or decline |
| Surgery and recovery | 4 to 6 weeks | Nephrectomy, follow-up, return to activity |
Total elapsed time usually falls between 3 and 6 months. A diabetes diagnosis adds the third row and frequently triggers repeat testing to confirm that a single abnormal value was not a fluke.
Misconceptions That Cost Candidates Time
The most common misconception is that controlled diabetes is the same as safe diabetes. Control over months, measured by HbA1c, says little about the structural state of the glomerulus. A donor with a perfect HbA1c can still have early nephropathy that only a biopsy or a sensitive albumin assay would detect.
A second misconception is that a family member in need overrides the criteria. Living donor selection is donor-centered by design; programs evaluate the donor's own risk, not the recipient's need. When a diabetic relative offers a kidney to a family member, the evaluation applies the same thresholds as for a stranger.
A third is that a prior refusal is permanent. Some candidates are declined for a reversible reason, such as temporary high blood pressure or a transient albumin elevation from exercise or fever. A repeat evaluation after correcting the reversible factor can succeed. Others are declined for a permanent reason, such as insulin dependence, and should not spend time and money on reapplication.
What to Actually Do If You Have Diabetes and Want to Donate
The productive path is to get quantified before the transplant team does. These actions improve the odds of a clean evaluation or a fast, honest answer.
- Request an HbA1c, a urine albumin-to-creatinine ratio, and a serum creatinine with eGFR from your primary care clinician, and bring the printed numbers.
- Ask for a confirmed diagnosis classification: gestational history only, prediabetes, type 2 on oral therapy, or insulin-dependent. The category drives everything.
- Get blood pressure measured on at least two occasions, since a single elevated reading can trigger a false exclusion.
- Contact the transplant center's living donor coordinator directly and ask whether their program accepts any donors with your specific diabetes category before starting formal evaluation.
- Keep a written log of glucose-lowering medications and doses; insulin use is the single most common disqualifier.
- Do not stop or alter diabetes medication to influence testing. Programs screen for this, and it endangers both you and the recipient.
Limits of the Evidence and Honest Uncertainty
The honest limitation is that long-term outcome data for diabetic living donors barely exist. Because most programs exclude diabetics, the published donor cohorts are overwhelmingly non-diabetic, and risk estimates for a diabetic donor are extrapolated from general-population diabetic kidney decline rather than measured in donors. That extrapolation could overstate or understate risk.
A second limitation is variability across programs. Two centers in the same city may reach opposite decisions on an identical candidate because their protocols differ on HbA1c ceiling, diabetes duration, and whether prediabetes counts. A candidate declined at one program is not necessarily declined everywhere, but shopping for a permissive center does not change the underlying biology.
A third is that donor registries track outcomes incompletely. Short-term surgical safety for living donation is well documented, with serious complication rates generally under 5 percent. The 20- and 30-year kidney outcomes for diabetic donors remain a genuine evidence gap, and any program that presents them as settled is overstating what is known.